Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02601014
Title Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center

prostate adenocarcinoma


Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.